The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This is a plain language summary of an article published inthe journal Brain. People with Alzheimer’s disease may receivetreatments that target amyloid-β – a protein in the brain thatis one of the key characteristics of Alzheimer’s disease whenit is present in higher levels than normal. This article is aboutamyloid-related imaging abnormalities (ARIA), which can beadverse events for people with Alzheimer’s disease receivingantibody treatments targeting amyloid-β (known as anti–amyloid-β antibody treatments). This article also discusses waysto identify and manage ARIA.This is a Plain Language Summary of Publication article (PLSP) from Neurodegenerative Disease Management that discusses amyloid-related imaging abnormalities (ARIA). People with Alzheimer’s disease may receive treatment targeting a protein called amyloid-β. ARIA can be an adverse event that can occur for people with Alzheimer’s disease receiving treatments targeting amyloid-β (anti-amyloid-β antibody treatments). This PLSP discusses ways to identify and manage ARIA.

Visit the site using the link to read the article.

This PLSP is based on an article called ‘Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics’ that was published in Brain. 

Visit the Oxford Academic site using the link to read the article.